Market cap gains far exceed historical trends: In an equivalent time period prior to the launch of their GLP-1 products, the combined market cap gains for Novo Nordisk and Eli Lilly was significantly lower at $197 billion3.5x less than the gains realized after the introduction of these products
CJC 1295 Ipamorelin can be beneficial for a wide range of people, including: Adults looking to improve muscle mass and strength Individuals aiming for better fat loss and metabolism Older adults seeking anti-aging benefits Athletes wanting faster recovery People experiencing low energy or poor sleep It is not recommended for pregnant or breastfeeding women, individuals under 18, or those with certain medical conditions
849-P: safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of an optimized dual GLP-1/GIP receptor agonist (BGM0504) in healthy SubjectsA phase ia, randomized, Double-Blind, Placebo-Controlled, ascending dose study
While just over 30% of people on Wegovy made it on their medication to the one-year mark in 2021, the year it was approved for weight loss, that figure had nearly doubled by 2024